Non-Alcoholic Steatohepatitis (NASH) Global Market 2024 – By Size, Share, Trends, Demand, Forecast To 2033 | NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc

The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $14.53 billion in 2028 at a compound annual growth rate (CAGR) of 33.7%.  The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-nash-global-market-report

Segmentation & Regional Insights
The non- alcoholic steatohepatitis (NASH) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral

North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2023. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8805&type=smp

Major Driver Impacting Market Growth
The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in April 2021, according to the COVID-19 and Obesity: The 2021 Atlas, a report published by the World Obesity Federation, a UK-based federation that represents professional members of the scientific 2021, percentage of overweight adults recorded more than 60% of the US population, however, the obesity percentage of male expected to reach 44.2% and female 44.4% by 2025 in the US population. Therefore, the rise in the cases of obesity will drive the growth of the Non-Alcoholic Steatohepatitis (NASH) market.

Key Industry Players
Major companies operating in the non-alcoholic steatohepatitis (NASH) market report are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Cempra Pharmaceuticals Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Vivus LLC, Arisaph Pharmaceuticals Inc., Galectin Therapeutics Inc., Raptor Pharmaceutical Inc., VERVA Technologies Pvt Ltd., Viking Therapeutics, Conatus Pharmaceuticals Inc., One Way Liver S.L., BioPredictive S.A.S., Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens

The non-alcoholic steatohepatitis (nash) market report table of contents includes:
1. Executive Summary
2. Non-Alcoholic Steatohepatitis (NASH) Market Characteristics
3. Non-Alcoholic Steatohepatitis (NASH) Market Trends And Strategies
4. Non-Alcoholic Steatohepatitis (NASH) Market – Macro Economic Scenario
5. Global Non-Alcoholic Steatohepatitis (NASH) Market Size and Growth
………………………………
32. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Benchmarking
33. Global Non-Alcoholic Steatohepatitis (NASH) Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis (NASH) Market
35. Non-Alcoholic Steatohepatitis (NASH) Market Future Outlook and Potential Analysis
36. Appendix

Explore the trending research reports from TBRC:
https://goodprnews.com/word-processing-software-global-market-size/
https://goodprnews.com/limestone-global-market-size/
https://goodprnews.com/luxury-writing-instruments-and-stationery-global-market-size/
https://topprnews.com/word-processing-software-global-market-share/
https://topprnews.com/limestone-global-market-share/
https://topprnews.com/luxury-writing-instruments-and-stationery-global-market-share/

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model